The 22.7% Q3 FY26 operating margin is a seasonal peak, not a structural run-rate. Q4 will be softer as fiscal year-end book-keeping compresses orders.

• Q3 FY26 operating margin: 22.7%
• Q4 in industrial automation is often softer than Q3 because customers lock in capex spend early in the year
• Revenue grew $4,553M → $4,873M = 7% YoY in Q3 FY26
• Organic growth is closer to 3–4% when backing out M&A contributions from NI

↩ rebuts: “Bull claims 22.7% margin is 'structural' and represents operational excellence”

The 59% EPS growth is the mirror image of a depressed denominator from non-recurring $242M bridge financing interest expense, not underlying business improvement. Normalizing for this one-time item, growth is 15–25% at best.

• 59% EPS growth (bull's claimed figure)
• Bridge financing interest expense in Q3 FY25: $242M
• Take $242M out of interest expense, normalize for tax, and TTM EPS is meaningfully higher
• The 'implied growth' collapses from 59% to something far more modest — maybe 15–25% if we're being generous

↩ rebuts: “Bull uses 59% EPS growth to justify the bull case as evidence of a step-function compounder”

The $3.7B TTM FCF is inflated by a one-time 36% spike in Q3 FY26 alone ($1.32B), likely from working capital release that will reverse. The 'compounder machine' narrative ignores 18-24 months of suppressed capital return during deleveraging.

• TTM FCF of $3.7B on the face
• Q3 FY26 alone produced $1.32B of FCF out of the trailing four-quarter total
• 36% spike in one quarter driven by working capital release, deferred collections, or timing of customer payments
• Deleveraging takes 18–24 months at the current pace
• EMR historically ran roughly $2.4B/yr in dividends + buybacks
• During deleveraging that compresses to $1.2–1.5B/yr

↩ rebuts: “Bull claims FCF will fund deleveraging AND aggressive buybacks as a 'compounder machine'”

The stock has failed three breakouts above $162-$164 over 2.5 months — this is distribution, not accumulation. Failed breakouts are the textbook setup for price decline. Downside to lower Bollinger/200 SMA ($144-145) is 9-10% versus only 7% upside to $170.

• August 5 high: $164.31
• October 5 high: $162.33
• Current price: $159.06
• Three attempts to break $162–$164 over two and a half months, all of which have failed
• Target $170 = 7% upside from $159
• Breakdown below $154.97 (20 SMA / middle Bollinger) opens a fall to lower Bollinger at $144.53 and 200 SMA at $144.41
• That's 9–10% downside
• Risk-reward asymmetry favors the bear by factor of ~1.4x

↩ rebuts: “Bull interprets the narrowing MACD histogram as consolidation of gains and 'coiling for a breakout'”

The 'higher-for-longer' rate environment increases hurdle rates for industrial capex. Marginal capex projects get shelved. The lag effect hasn't hit EMR's order book yet. EMR is not meaningfully an AI stock — AI/data center exposure is at best 2-4% incremental revenue on an $18.6B revenue base.

• 96% no-cut probability from Polymarket
• $5 trillion-plus outstanding stock of corporate debt being rolled at 5%+ yields
• Healthcare proxy — mortgage rates at three-year highs
• High and not falling is itself the conditions under which industrial orders begin to wobble 6–12 months out
• EMR is not an AI stock
• AspenTech predates the AI boom by 20 years
• Data center buildout represents a tiny slice of EMR's revenue mix
• This is at best 2–4% incremental revenue, not a thesis-changing tailwind

↩ rebuts: “Bull cites soft-landing data (6% recession odds) to frame it as Goldilocks environment”

EMR trades at premium multiples (34.8x trailing P/E, 21.9x forward P/E) on mid-single-digit organic growth, with a stressed balance sheet (current ratio 0.90, negative tangible book of -$7.4B) and $4.8B in net debt issued in FY25 that will consume FCF for 12-18 months. Street consensus already bakes in $7.27 EPS — any disappointment triggers multiple compression.

• 34.8x trailing P/E
• 21.9x forward P/E
• Mid-single-digit organic growth (3-4%)
• Current ratio of 0.90
• Current liabilities exceed current assets by ~$1.2B
• Negative tangible book of -$7.4B
• $4.8B in net debt issuance in FY25
• Street consensus already has $7.27 of forward EPS baked in
• If November print comes in at $6.50–7.00 instead of $7.27, the stock re-rates lower
• If guidance for FY27 disappoints, the multiple compresses hard

↩ rebuts: “Bull claims forward P/E of 21.9x is reasonable for a 20% FCF margin business”

The $7.4B negative tangible book represents goodwill that becomes impaired if NI integration synergies disappoint or AspenTech growth slows. A hypothetical $3-4B goodwill impairment would be a 15–20% equity hit and would vaporize years of buybacks.

• EMR equity is $20.3B today
• A hypothetical $3-4B goodwill impairment (well within historical industrial-tech precedent) would be a 15–20% equity hit
• Goodwill gets impaired — and impairment charges come straight out of equity
• The bull has given no scenario where integration disappoints

↩ rebuts: “Bull dismisses negative tangible book as just 'productive intangibles'”